Fiera Capital Corp Has $329,000 Stock Holdings in Simulations Plus, Inc. $SLP

Fiera Capital Corp decreased its stake in Simulations Plus, Inc. (NASDAQ:SLP) by 19.7% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,869 shares of the technology company’s stock after selling 4,631 shares during the quarter. Fiera Capital Corp owned approximately 0.09% of Simulations Plus worth $329,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of SLP. AlphaQuest LLC acquired a new position in shares of Simulations Plus in the second quarter worth $69,000. US Bancorp DE grew its stake in Simulations Plus by 15.6% in the first quarter. US Bancorp DE now owns 6,576 shares of the technology company’s stock valued at $161,000 after purchasing an additional 889 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Simulations Plus in the first quarter valued at about $210,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Simulations Plus by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,493 shares of the technology company’s stock worth $233,000 after purchasing an additional 390 shares during the last quarter. Finally, Savvy Advisors Inc. purchased a new stake in shares of Simulations Plus during the 1st quarter worth about $249,000. 78.08% of the stock is currently owned by hedge funds and other institutional investors.

Simulations Plus Stock Up 0.5%

NASDAQ:SLP opened at $17.31 on Friday. The company’s 50 day moving average is $16.07 and its 200-day moving average is $18.84. Simulations Plus, Inc. has a 12 month low of $12.39 and a 12 month high of $37.67. The firm has a market cap of $348.40 million, a price-to-earnings ratio of -5.50 and a beta of 0.98.

Analyst Ratings Changes

SLP has been the subject of several recent research reports. Cowen initiated coverage on Simulations Plus in a research note on Tuesday, September 30th. They issued a “hold” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Simulations Plus in a research note on Wednesday, October 8th. Zacks Research raised shares of Simulations Plus from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 28th. KeyCorp restated a “sector weight” rating on shares of Simulations Plus in a research note on Wednesday, October 29th. Finally, TD Cowen began coverage on shares of Simulations Plus in a research note on Tuesday, September 30th. They issued a “hold” rating and a $16.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Simulations Plus presently has a consensus rating of “Hold” and a consensus price target of $24.40.

Simulations Plus Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.